VHL Alliance Warrior Call Event Highlights Progress in Controlling Tumor Growth
Nobel Prize Winner cites landmark progress in cancer research and treatment
News provided by
Share this article
Share this article
BOSTON, May 13, 2021 /PRNewswire/ In remarks at the 2021 Warrior Call event last night, a signature event for the VHL Alliance during VHL (von Hippel-Lindau disease) Awareness month, William G. Kaelin Jr., MD, noted incredible progress in understanding how tumors grown and possible breakthroughs in cancer treatment. Dr. Kaelin, based at Harvard s Dana-Farber Cancer Institute, is co-recipient of the 2019 Nobel Prize in Medicine for his team s work on Hypoxia-Inducible factor (HIF), an important tumor growth mechanism.
2021 Research Grant Recipients Announced by the VHL Alliance
Global Research Program Supports Curing Cancer through VHL
News provided by
Share this article
Share this article
BOSTON, Jan. 19, 2021 /PRNewswire/ The VHL Alliance (VHLA) today announced the 2021 recipients of the VHLA Competitive Research Grant Program. This year, three grantees were chosen. Scientists are increasingly aware that curing von Hippel-Lindau disease, a genetic form of cancer – is a key step to curing cancer, leading to a significant increase in the quality of research grant applicants in the program year after year.
Over 20 top VHLA researchers from across the US, Canada, and Europe were involved in reviewing and selecting those projects which have the greatest potential to make advances toward Curing Cancer through VHL. For the second year in a row, responding to the increase in quality applications, the VHLA Board of Directors voted to expand the annual budget for research.